Linearized DNA Template for Homogeneous mRNA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing clinical-grade mRNA therapeutics face challenges in achieving high purity and potency, consistency, and compliance with good manufacturing practices (cGMP), particularly in controlling poly A tail length and minimizing impurities during in vitro transcription.
Innovation Solution
The method employs a non-amplified, linearized DNA template in an in vitro transcription reaction, excluding DNase and using enzymatic capping to produce RNA transcripts, which are then purified via chromatographic methods, ensuring high purity and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a tailless DNA template is used with post-transcriptional poly A polymerase, then poly A tail containing mRNA can be generated, but tail length control is difficult and tail length distribution becomes heterogeneous
Solution Approach 1:
The poly A tail is incorporated into the DNA template during PCR amplification before transcription occurs. This preliminary incorporation ensures that the poly A tract is precisely defined in the template, leading to uniform tail length in the final mRNA product without requiring post-transcriptional addition.
Solution Approach 2:
The patent replaces the enzymatic mechanism (poly A polymerase addition) with a template-directed mechanism where the poly A tract is encoded in the DNA template itself. This substitution provides precise control over tail length through sequence design rather than enzymatic control.
2Quantity of substance
If PCR is used to generate DNA templates containing poly A:T tracts, then poly A tail can be introduced, but additional impurities are introduced through PCR primers and amplification steps
Solution Approach 1:
The patent extracts and removes the PCR amplification step from the template generation process. By using plasmid linearization instead of PCR, the source of primer-related impurities is eliminated while retaining the ability to incorporate poly A tracts into the template.
Solution Approach 2:
The patent discards the PCR amplification process entirely in favor of plasmid linearization. The plasmid template is linearized with restriction enzymes and used directly as the transcription template, eliminating the need for PCR and its associated impurity generation.
3Object-generated harmful factors
If DNase is used during purification, then DNA template can be removed, but additional processing steps and potential RNA degradation are introduced
Solution Approach 1:
The patent extracts and removes the DNase treatment step from the purification process. By using a linearized plasmid template with a poly A tract, DNA-RNA separation is achieved through chromatographic methods alone, eliminating the need for enzymatic DNA degradation and associated complexity.
4Quantity of substance
If chemical cap analogs are used for 5' capping, then capped mRNA can be produced, but uncapped species and immunogenicity remain as impurities
Solution Approach 1:
The patent replaces chemical capping methods with enzymatic capping using Vaccinia guanylyltransferase. This enzymatic approach provides more complete and controlled capping, minimizing uncapped species and reducing immunogenicity while maintaining productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in homogeneous RNA transcripts with increased purity and potency, reducing immunogenicity and improving process productivity by minimizing uncapped species and impurities, while maintaining scalability and compliance with cGMP standards.
Implementation Method 1
Disclosed is a method for production of an RNA transcript, e.g., mRNA, using a non-amplified, linearized DNA template in an in vitro transcription reaction to generate the RNA transcript
Implementation Method 2
The RNA transcript is enzymatically capped post transcriptionally at the 5' end using Vaccinia guanylyltransferase, guanosine triphosphate and s-adenosyl-L-methionine to yield cap 0 structure
Implementation Method 3
The RNA transcript is purified via chromatographic methods, ensuring high purity and potency
Data Source
AI summary
Described are methods for production of RNA transcripts using a non-amplified, linearized DNA tempate in an in vitro transcription reaction. Enzymatic 5 ' capping and oligo dT purification can also be included in the methods.